Efficacy and Safety of Docetaxel or Epirubicin, Combined with Cisplatin and Fluorouracil, (DCF and ECF) Regimens as First Line Chemotherapy for Advanced Gastric Cancer: a Retrospective Analysis from Turkey

Teker, Fatih; Yılmaz, Bahiddin; Kemal, Yasemin; Kut, Engin; Yücel, İdris

doi:10.7314/apjcp.2014.15.16.6727

Cited by 8 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From our results, four studies[9,10,12,19] showed that DCF significantly prolonged the OS of patients compared with ECF, and three studies[8,9,19] showed that DCF significantly prolonged the PFS of patients compared with ECF. The results were beneficial to the translation of OS and PFS from the DCF regimen to the pooled median survival time of approximately 1 mo.…”

Section: Discussionmentioning

confidence: 65%

“…Our results showed an advantage in the improvement of ORR and DCR in the DCF group. Only one study[12] showed that the ORR of the DCF group was lower than that of the ECF group (26.2% vs 29.5%, respectively). These results might be because docetaxel had better efficacy, and the patient's response to this drug was relatively high.…”

Section: Discussionmentioning

confidence: 99%

“…However, in other studies, opposite results were obtained, and the ECF regimen had better antitumor efficacy and better quality of life for advanced gastric cancer[10,11]. In a retrospective analysis from Turkey, Teker et al reported that DCF and ECF had similar efficacy and tolerability in treating advanced gastric cancer[12].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin, and 5-fluorouracil regimen for advanced gastric cancer: A systematic review and meta-analysis

Li¹,

Chen²,

Luo³

et al. 2019

WJCC

View full text Add to dashboard Cite

BACKGROUND As the first-line regimens for the treatment of advanced gastric cancer, both docetaxel, cisplatin, and 5-fluorouracil (DCF) and epirubicin, cisplatin, and 5-fluorouracil (ECF) regimens are commonly used in clinical practice, but there is still controversy about which is better. AIM To compare the efficacy and safety of DCF and ECF regimens by conducting this meta-analysis. METHODS Computer searches in PubMed, EMBASE, Ovid MEDLINE, Science Direct, Web of Science, The Cochrane Library and Scopus were performed to find the clinical studies of all comparisons between DCF and ECF regimens. We used progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse effects (AEs) as endpoints for analysis. RESULTS Our meta-analysis included seven qualified studies involving a total of 598 patients. The pooled hazard ratios between the DCF and ECF groups were comparable in PFS (95%CI: 0.58-1.46, P = 0.73), OS (95%CI: 0.65-1.10, P = 0.21), and total AEs (95%CI: 0.93-1.29, P = 0.30). The DCF group was significantly better than the ECF group in terms of ORR (95%CI: 1.13-1.75, P = 0.002) and DCR (95%CI: 1.03-1.41, P = 0.02). However, the incidence rate of grade 3-4 AEs was also greater in the DCF group than in the ECF group (95%CI: 1.16-1.88, P = 0.002), especially for neutropenia and febrile neutropenia. CONCLUSION With better ORR and DCR values, the DCF regimen seems to be more suitable for advanced gastric cancer than the ECF regimen. However, the higher rate of AEs in the DCF group still needs to be noticed.

show abstract

Section: Discussionmentioning

confidence: 65%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin, and 5-fluorouracil regimen for advanced gastric cancer: A systematic review and meta-analysis

Li¹,

Chen²,

Luo³

et al. 2019

WJCC

View full text Add to dashboard Cite

show abstract

“…[32,33] The second-line chemotherapy has been proved to be effective in the patients who were not responsive to first-line chemotherapy. [9,28,34] However, the third-line chemotherapy and its regimens for progressive gastric cancer after the second-line chemotherapy is largely not evidence based, and treatment varies considerably in terms reagent selection and treatment plan. The current systematic review found that the most commonly used single reagent for third-line chemotherapy is irinotecan or paclitaxel/docetaxel.…”

Section: Discussionmentioning

confidence: 99%

Third-line chemotherapy in advanced gastric cancer

2017

View full text Add to dashboard Cite

show abstract

“…Thus, AGC remains a common malignancy worldwide that seriously reduces the quality of life of patients, and the prognosis of AGC patients remains poor. In general, the combination of trastuzumab and cisplatin is the chemotherapy regimen that is most frequently used to treat AGC, 1 , 2 although patients receiving that treatment experience considerable adverse effects and they endure many inconveniences. 3 S-1, as a new novel oral fluoropyrimidine agent, has already been confirmed to show promising anticancer efficacy for AGC.…”

Section: Introductionmentioning

confidence: 99%

A Retrospective Comparison of Trastuzumab Plus Cisplatin and Trastuzumab Plus Capecitabine in Elderly HER2-Positive Advanced Gastric Cancer Patients

Zhu

Zhou³

2015

Medicine

View full text Add to dashboard Cite

A combination of trastuzumab and cisplatin or trastuzumab and capecitabine has been confirmed to be effective for treating adverse effects in with HER2-positive advanced gastric cancer (AGC) patients. We retrospectively compared the activity and safety of trastuzumab plus cisplatin (HP) and trastuzumab plus capecitabine (HX) for elderly HER2-positive AGC patients.Ninety two HER2-positive AGC patients were included in this study; of those 48 patients received trastuzumab (course 1, 8 mg/kg followed by course 2, onward, 6 mg/kg on day 1) plus cisplatin (60 mg/m2) intravenously on day 1 of a 3-week cycle and 44 patients received trastuzumab (course 1, 8 mg/kg; course 2 onward, 6 mg/kg) plus intravenous oral capecitabine (1000 mg/m2 twice daily on days 1–14), every 3 weeks. The primary end point was overall survival (OS). The secondary end points included objective response rate (ORR), progression-free survival (PFS), and toxicity.The median age was 71 years in both groups. The median OS was 15.5 months in the HP group and 17.0 months in the HX group, with no significant difference between the 2 groups (P = 0.78). There were also no significant differences in PFS (median 6.6 months vs 7.2 months, respectively; P = 0.90) and ORR (58.3% vs 59.1%, respectively; P = 1.00) between the HP group and the HX group. The major grade 3 or 4 adverse events in the HP group and the HX group were neutropenia (35.4% vs 29.5%, respectively), followed by anorexia (25.0% vs 22.7%, respectively), and anemia (16.7% vs 13.6%, respectively), no significant differences were observed.HP and HX were associated with similar efficacy and safety in HER2-positive AGC patients.

show abstract

Efficacy and Safety of Docetaxel or Epirubicin, Combined with Cisplatin and Fluorouracil, (DCF and ECF) Regimens as First Line Chemotherapy for Advanced Gastric Cancer: a Retrospective Analysis from Turkey

Cited by 8 publications

References 15 publications

Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin, and 5-fluorouracil regimen for advanced gastric cancer: A systematic review and meta-analysis

Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin, and 5-fluorouracil regimen for advanced gastric cancer: A systematic review and meta-analysis

Third-line chemotherapy in advanced gastric cancer

A Retrospective Comparison of Trastuzumab Plus Cisplatin and Trastuzumab Plus Capecitabine in Elderly HER2-Positive Advanced Gastric Cancer Patients

Contact Info

Product

Resources

About